rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fractures
Conditions
Fractures
Trial Timeline
Nov 1, 2006 → Mar 1, 2010
NCT ID
NCT00387686About rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM
rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM is a phase 2/3 stage product being developed by Pfizer for Fractures. The current trial status is terminated. This product is registered under clinical trial identifier NCT00387686. Target conditions include Fractures.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00387686 | Phase 2/3 | Terminated |
Competing Products
12 competing products in Fractures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK5211 + Placebo | Viking Therapeutics | Phase 2 | 47 |
| Teriparatide + Placebo | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Zoledronic Acid 5Mg/Bag 100Ml Inj + sodium chloride | Roche | Approved | 85 |
| Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC | Amgen | Phase 3 | 76 |
| rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| InductOs | Pfizer | Approved | 84 |
| rhBMP-2/CPM | Pfizer | Phase 1 | 32 |
| rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| Tranexamic Acid plus standard of care | Pfizer | Approved | 84 |
| CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 | Pfizer | Phase 2 | 51 |
| enoxaparin (XRP4563) | Sanofi | Phase 3 | 76 |